vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and TETRA TECH INC (TTEK). Click either name above to swap in a different company.
TETRA TECH INC is the larger business by last-quarter revenue ($1.2B vs $699.9M, roughly 1.7× QuidelOrtho Corp). TETRA TECH INC runs the higher net margin — 8.7% vs -104.7%, a 113.4% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-3.7% vs -14.8%). TETRA TECH INC produced more free cash flow last quarter ($68.1M vs $-94.7M). Over the past eight quarters, TETRA TECH INC's revenue compounded faster (-1.6% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Tetra Tech, Inc. is an American consulting and engineering services firm based in Pasadena, California. The company provides consulting, engineering, program management, and construction management services in the areas of water, environment, infrastructure, resource management, energy, and international development.
QDEL vs TTEK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $1.2B |
| Net Profit | $-733.0M | $105.2M |
| Gross Margin | — | 18.2% |
| Operating Margin | -100.7% | 11.6% |
| Net Margin | -104.7% | 8.7% |
| Revenue YoY | -3.7% | -14.8% |
| Net Profit YoY | -3583.4% | 13424.7% |
| EPS (diluted) | $-10.78 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2B | ||
| Q3 25 | $699.9M | $1.3B | ||
| Q2 25 | $613.9M | $1.4B | ||
| Q1 25 | $692.8M | $1.3B | ||
| Q4 24 | $707.8M | $1.4B | ||
| Q3 24 | $727.1M | $1.4B | ||
| Q2 24 | $637.0M | $1.3B | ||
| Q1 24 | $711.0M | $1.3B |
| Q4 25 | — | $105.2M | ||
| Q3 25 | $-733.0M | $127.9M | ||
| Q2 25 | $-255.4M | $113.8M | ||
| Q1 25 | $-12.7M | $5.4M | ||
| Q4 24 | $-178.4M | $778.0K | ||
| Q3 24 | $-19.9M | $96.2M | ||
| Q2 24 | $-147.7M | $85.8M | ||
| Q1 24 | $-1.7B | $76.4M |
| Q4 25 | — | 18.2% | ||
| Q3 25 | — | 20.6% | ||
| Q2 25 | — | 18.4% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | — | 15.6% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | — | 16.6% | ||
| Q1 24 | — | 16.6% |
| Q4 25 | — | 11.6% | ||
| Q3 25 | -100.7% | 13.6% | ||
| Q2 25 | -29.4% | 12.0% | ||
| Q1 25 | 4.7% | 3.0% | ||
| Q4 24 | -14.2% | 1.6% | ||
| Q3 24 | 2.1% | 10.4% | ||
| Q2 24 | -18.4% | 9.6% | ||
| Q1 24 | -247.3% | 9.4% |
| Q4 25 | — | 8.7% | ||
| Q3 25 | -104.7% | 9.6% | ||
| Q2 25 | -41.6% | 8.3% | ||
| Q1 25 | -1.8% | 0.4% | ||
| Q4 24 | -25.2% | 0.1% | ||
| Q3 24 | -2.7% | 7.0% | ||
| Q2 24 | -23.2% | 6.4% | ||
| Q1 24 | -239.9% | 6.1% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | $-10.78 | $0.48 | ||
| Q2 25 | $-3.77 | $0.43 | ||
| Q1 25 | $-0.19 | $0.02 | ||
| Q4 24 | $-2.54 | $0.00 | ||
| Q3 24 | $-0.30 | $-3.18 | ||
| Q2 24 | $-2.20 | $1.59 | ||
| Q1 24 | $-25.50 | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $269.4M |
| Total DebtLower is stronger | $2.5B | $837.1M |
| Stockholders' EquityBook value | $2.0B | $1.8B |
| Total Assets | $5.7B | $4.3B |
| Debt / EquityLower = less leverage | 1.23× | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $269.4M | ||
| Q3 25 | $98.1M | $167.5M | ||
| Q2 25 | $151.7M | $242.8M | ||
| Q1 25 | $127.1M | $179.4M | ||
| Q4 24 | $98.3M | $248.1M | ||
| Q3 24 | $143.7M | $232.7M | ||
| Q2 24 | $107.0M | $212.3M | ||
| Q1 24 | $78.5M | $210.3M |
| Q4 25 | — | $837.1M | ||
| Q3 25 | $2.5B | $766.4M | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | $1.0B | ||
| Q4 24 | $2.1B | $888.5M | ||
| Q3 24 | $2.2B | $812.6M | ||
| Q2 24 | $2.2B | $861.8M | ||
| Q1 24 | $2.2B | $951.0M |
| Q4 25 | — | $1.8B | ||
| Q3 25 | $2.0B | $1.8B | ||
| Q2 25 | $2.8B | $1.7B | ||
| Q1 25 | $3.0B | $1.6B | ||
| Q4 24 | $3.0B | $1.7B | ||
| Q3 24 | $3.2B | $1.8B | ||
| Q2 24 | $3.2B | $1.7B | ||
| Q1 24 | $3.3B | $1.6B |
| Q4 25 | — | $4.3B | ||
| Q3 25 | $5.7B | $4.3B | ||
| Q2 25 | $6.4B | $4.4B | ||
| Q1 25 | $6.5B | $4.2B | ||
| Q4 24 | $6.4B | $4.2B | ||
| Q3 24 | $6.8B | $4.2B | ||
| Q2 24 | $6.7B | $4.1B | ||
| Q1 24 | $6.7B | $4.1B |
| Q4 25 | — | 0.45× | ||
| Q3 25 | 1.23× | 0.43× | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | 0.64× | ||
| Q4 24 | 0.72× | 0.53× | ||
| Q3 24 | 0.68× | 0.44× | ||
| Q2 24 | 0.70× | 0.52× | ||
| Q1 24 | 0.68× | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $72.3M |
| Free Cash FlowOCF − Capex | $-94.7M | $68.1M |
| FCF MarginFCF / Revenue | -13.5% | 5.6% |
| Capex IntensityCapex / Revenue | 7.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 0.69× |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | $497.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $72.3M | ||
| Q3 25 | $-45.5M | $100.8M | ||
| Q2 25 | $-46.8M | $349.6M | ||
| Q1 25 | $65.6M | $-5.8M | ||
| Q4 24 | $63.7M | $13.1M | ||
| Q3 24 | $117.9M | $105.6M | ||
| Q2 24 | $-97.9M | $140.9M | ||
| Q1 24 | $-700.0K | $102.9M |
| Q4 25 | — | $68.1M | ||
| Q3 25 | $-94.7M | $95.6M | ||
| Q2 25 | $-84.3M | $345.6M | ||
| Q1 25 | $9.4M | $-11.8M | ||
| Q4 24 | $16.5M | $9.6M | ||
| Q3 24 | $71.4M | $98.8M | ||
| Q2 24 | $-133.2M | $137.1M | ||
| Q1 24 | $-66.8M | $98.9M |
| Q4 25 | — | 5.6% | ||
| Q3 25 | -13.5% | 7.2% | ||
| Q2 25 | -13.7% | 25.2% | ||
| Q1 25 | 1.4% | -0.9% | ||
| Q4 24 | 2.3% | 0.7% | ||
| Q3 24 | 9.8% | 7.2% | ||
| Q2 24 | -20.9% | 10.2% | ||
| Q1 24 | -9.4% | 7.9% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 7.0% | 0.4% | ||
| Q2 25 | 6.1% | 0.3% | ||
| Q1 25 | 8.1% | 0.4% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 6.4% | 0.5% | ||
| Q2 24 | 5.5% | 0.3% | ||
| Q1 24 | 9.3% | 0.3% |
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.79× | ||
| Q2 25 | — | 3.07× | ||
| Q1 25 | — | -1.08× | ||
| Q4 24 | — | 16.79× | ||
| Q3 24 | — | 1.10× | ||
| Q2 24 | — | 1.64× | ||
| Q1 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
TTEK
| Commercial International Services Group | $704.2M | 58% |
| Commercial | $225.4M | 19% |
| State And Local Government | $171.5M | 14% |
| Cost Plus | $95.1M | 8% |
| Related Party | $15.8M | 1% |
